Apimeds Pharmaceuticals US, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-627.8K | $-627.8K | — | $70.0K |
| FY2024 | $-733.5K | $-733.5K | — | — |
| FY2025 | $-8.9M | $-9.0M | $57.3K | $1.6M |
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-627.8K | $-627.8K | — | $70.0K |
| FY2024 | $-733.5K | $-733.5K | — | — |
| FY2025 | $-8.9M | $-9.0M | $57.3K | $1.6M |